| 标题： | 中国胰腺囊性病灶诊断专家共识 |
| title： | Chinese experts‘ consensus on pancreatic cystic lesions |
| 版本： | 改编版 |
| version： | Adapted |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊断 |
| field： | Diagnosis |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 各级医疗机构的消化内科、胰腺外科、影像科的从事胰腺疾病相关工作的的临床医师、护理人员、技术人员及相关教学、科研工作人员。 |
| Guide users： | This consensus is applicable to clinicians, nurses, technicians from departments of gastroenterology, pancreatic surgery and medical imaging who are engaging in pancreatic diseases and relevant teaching and scientific research staffs. |
| 证据分级方法： | 采用推荐意见分级的评估、制订及评价（grading of recommendations assessment，development，and evaluation，GRADE）系统评估证据质量和推荐强度。 高质量（A）：非常有把握观察值接近真实值 中等质量（B）：对观察值有中等把握：观察值有可能接近真实值，但也有可能差别很大 低质量（C）：对观察值的把握有限：观察值可能与真实值有很大差别 极低质量（D）：对观察值几乎没有把握：观察值与真实值可能有极大差别 |
| Evidence grading method： | The grading of recommendations assessment, development, and evaluation (grade) system is used to evaluate the evidence quality and recommendation strength. High = Further research is unlikely to change our confidence in the estimate of effect. Moderate = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low = Any estimate of effect is very uncertain. |
| 制定单位： | 海军医科大学附属第一医院 |
| Formulating unit： | The First Affiliated Hospital of Naval Medical University |
| 注册时间： | 2022-05-02 |
| Registration time： | |
| 注册编号： | IPGRP-2022CN252 |
| Registration number： | |
| 指南制订的目的： | 胰腺囊性肿瘤（pancreatic cystic neoplasm，PCN）包含了胰腺导管内乳头状黏液性肿瘤（intraductal papillary mucinous neoplasm，IPMN）、黏液性囊腺瘤（mucinous cystic neoplasm，MCN）、浆液性囊腺瘤（serous cystic neoplasm，SCN）及其他少见囊性病变。上述PCN的生物学特性及恶变风险均不尽相同。随着医学影像学的发展，PCN检出率逐年增加，因此优化PCN随访策略以评价其恶变几率及外科手术风险已成为日趋重要的临床问题。 |
| Purpose of the guideline： | Pancreatic cystic neoplasm (PCN) include intraductal papillary mucinous tumor (IPMN), mucinous cystadenoma (MCN), serous cystadenoma (SCN) and other rare cystic lesions. The biological features and risk of malignant transformation of the PCNs vary. With the development of medical imaging, the detection rate of PCNs is increasing. Therefore, optimizing the follow-up strategy of PCN to assess its malignant transformation probability and surgical risk has become an increasingly important clinical issue. |
最新注册
